amibegron Report issue

Small molecule Experimental
AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW
  • Now
Amibegron (SR-58,611A) was a drug developed by Sanofi-Aventis which acts as a selective agonist for the β3 adrenergic receptor. It is the first orally active β3 agonist developed that is capable of entering the central nervous system, and has antidepressant and anxiolytic effects.   Wikipedia

Chemistry

  • SMILES: CCOC(=O)COc1ccc2CC[C@@H](Cc2c1)NC[C@H](O)c3cccc(Cl)c3
  • InChIKey: RDJQCOBTKKAQAH-FPOVZHCZSA-N
  • Mol. Mass: 403.91
  • ALogP: 3.46
  • ChEMBL Molecules:
    amibegron  
    amibegron hydrochloride  
More Chemistry

Pharmacology

Alternative names

acetic acid, ((7-((2-(3-chlorophenyl)-2-hydroxyethyl)amino)-5,6,7,8-tetrahydro-2-naphthalenyl)oxy)-, ethyl ester, hydrochloride, (r-(r*,s*))- | amibegron | amibegron hcl | amibegron hydrochloride | sr 58611 | sr-58611 | sr58611a | sr 58611a | sr-58611a

Organizations (1)

Research & Development (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (5)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (5)


 

Anxiety ()

Anxiety Disorders (Phase 3)

Depression (Phase 3)

Depressive Disorder (Phase 3)

Depressive Disorder, Major (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 14
  • # of Trial Organizations: 1

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue